Skip to Main Content
Contribute Try STAT+ Today

Top of the morning to you, and a fine one it is. A shiny sun and clear skies are enveloping the Pharmalot campus, where the official mascot is contentedly snoozing in a corner and street life is buzzing nearby. As for us, we are engaged in our usual ritual of brewing cups of stimulation, which we need more than ever since we have some upcoming chats with public radio types. Wish us luck. The flavor today, by the way, is glazed doughnut. Yum. Meanwhile, here are some tidbits to get you going. Hope your day is successful and you conquer the world. …

A panel of experts convened by the U.S. Food and Drug Administration voted by a slim margin to recommend the agency authorize the Covid treatment developed by Merck (MRK) and Ridgeback Biotherapeutics, after a vigorous debate about the risks and benefits of the first oral drug to combat the coronavirus, STAT writes. The panel voted 13-10 that the pill, called molnupiravir, should be authorized, although members expressed concerns that, if used in pregnancy it could cause birth defects. Discussions frequently turned to whether or not panelists trusted the effectiveness data on the drug, even when they were talking about other topics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Create a display name to comment

This name will appear with your comment